Literature DB >> 25361220

Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial.

William B Robb1, Laetitia Dahan, Françoise Mornex, Emilie Maillard, Pascal-Alexandre Thomas, Bernard Meunier, Valérie Boige, Denis Pezet, Valérie Le Brun-Ly, Jean-François Bosset, Jean-Yves Mabrut, Jean-Pierre Triboulet, Laurent Bedenne, Jean-François Seitz, Christophe Mariette.   

Abstract

OBJECTIVE: The study objectives were to analyze the impact of the number of lymph nodes (LNs) reported as resected (NLNr) and the number of LNs invaded (NLNi) on the prognosis of esophageal cancer (EC) after neoadjuvant chemoradiotherapy.
BACKGROUND: Pathological LN status is a major disease prognostic factor and marker of surgical quality. The impact of neoadjuvant chemoradiation (nCRT) on LN status remains poorly studied in EC.
METHODS: Post hoc analysis from a phase III randomized controlled trial comparing nCRT and surgery (group nCRT) to surgery alone (group S) in stage I and II EC (NCT00047112). Only patients who underwent surgical resection were considered (n = 170).
RESULTS: nCRT resulted in tumoral downstaging (pT0, 40.7% vs 1.1%, P < 0.001), LN downstaging (pN0, 69.1% vs 47.2%, P = 0.016), and reduction in the median NLNr [16.0 (range, 0-47.0) vs 22.0 (range, 3.0-58.0), P = 0.001] and NLNi [0 (range, 0-25) vs 1.0 (range, 0-25), P = 0.001]. A good histological response (TRG1/2) in the resected esophageal specimen correlated with reduced median NLNi [0 (range, 0-10) vs 1.0 (range, 0-4), P = 0.007]. After adjustment by treatment, NLNi [hazards ratio (HR) (1-3 vs 0) 3.5, 95% confidence interval (CI): 2.3-5.5, and HR (>3 vs 0) 3.5, 95% CI: 2.0-6.2, P < 0.001] correlated with prognosis, whereas NLNr [HR (<15 vs ≥15) 0.95, 95% CI: 0.6-1.4, P = 0.807 and HR (<23 vs ≥23) 1.4, 95% CI: 0.9-2.0, P = 0.131] did not. In Poisson regression analysis, nCRT was an independent predictive variable for reduced NLNr [exp(coefficient) 0.80, 95% CI: 0.66-0.96, P = 0.018].
CONCLUSIONS: nCRT is not only responsible for disease downstaging but also predicts fewer LNs being identified after surgical resection for EC. This has implications for the current quality criteria for surgical resection.

Entities:  

Mesh:

Year:  2015        PMID: 25361220     DOI: 10.1097/SLA.0000000000000991

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  14 in total

Review 1.  [Oncologic esophageal resection and reconstruction : Open, hybrid, minimally invasive or robotic?]

Authors:  I Gockel; D Lorenz
Journal:  Chirurg       Date:  2017-06       Impact factor: 0.955

2.  Comparative Quantitative Lymph Node Assessment in Localized Esophageal Cancer Patients After R0 Resection With and Without Neoadjuvant Chemoradiation Therapy.

Authors:  Danica N Giugliano; Adam C Berger; Michael J Pucci; Ernest L Rosato; Nathaniel R Evans; Hanna Meidl; Casey Lamb; Daniel Levine; Francesco Palazzo
Journal:  J Gastrointest Surg       Date:  2017-06-29       Impact factor: 3.452

Review 3.  Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management.

Authors:  Masahiko Ikebe; Masaru Morita; Manabu Yamamoto; Yasushi Toh
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-05-10

4.  Does the lymph node yield affect survival in patients with esophageal cancer receiving neoadjuvant therapy plus esophagectomy? A systematic review and updated meta-analysis.

Authors:  Donglai Chen; Yiming Mao; Yuhang Xue; Yonghua Sang; Desen Liu; Yongbing Chen
Journal:  EClinicalMedicine       Date:  2020-07-31

5.  Neoadjuvant therapy in relation to lymphadenectomy and resection margins during surgery for oesophageal cancer.

Authors:  Joonas H Kauppila; Karl Wahlin; Pernilla Lagergren; Jesper Lagergren
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

6.  A Population-based Study on Lymph Node Retrieval in Patients with Esophageal Cancer: Results from the Dutch Upper Gastrointestinal Cancer Audit.

Authors:  L R van der Werf; J L Dikken; M I van Berge Henegouwen; V E P P Lemmens; G A P Nieuwenhuijzen; B P L Wijnhoven
Journal:  Ann Surg Oncol       Date:  2018-03-09       Impact factor: 5.344

7.  Minimally Invasive Esophagectomy the Standard of Care: Experience from a Tertiary Care Cancer Center from India.

Authors:  Rao T Subramanyeshwar; K V V N Raju; Sujit Chyau Patnaik; Ajesh Raj Saksena; Reddy R Pratap; Basanth Kumar Rayani; Vibhavari Milind Naik; Syed Nusrath
Journal:  Indian J Surg Oncol       Date:  2021-03-13

8.  Impact of the number of resected lymph nodes on survival after preoperative radiotherapy for esophageal cancer.

Authors:  San-Gang Wu; Zhao-Qiang Zhang; Wen-Ming Liu; Zhen-Yu He; Feng-Yan Li; Huan-Xin Lin; Jia-Yuan Sun; Hui Lin; Qun Li
Journal:  Oncotarget       Date:  2016-04-19

9.  Evaluating the eighth edition TNM staging system for esophageal cancer among patients receiving neoadjuvant therapy: A SEER study.

Authors:  Yonggang Yuan; Ge Ma; Xuelei Hu; Qingyuan Huang
Journal:  Cancer Med       Date:  2020-05-11       Impact factor: 4.452

10.  Adequate Lymphadenectomy as a Quality Measure in Esophageal Cancer: Is there an Association with Treatment Approach?

Authors:  Cary Jo R Schlick; Rhami Khorfan; David D Odell; Ryan P Merkow; David J Bentrem
Journal:  Ann Surg Oncol       Date:  2020-06-09       Impact factor: 4.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.